Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$23.76 USD
+2.03 (9.34%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $23.80 +0.04 (0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Arcturus Therapeutics Holdings Inc. [ARCT]
Reports for Purchase
Showing records 61 - 80 ( 140 total )
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Recap: Expecting Key Data Readouts From COVID-19
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
ARCT-021 COVID-19 mRNA Vaccine Dosing Begins in Phase 1/2 Study as Planned; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Nervous Race for Frontrunners, More Relaxed "Game" for the Runner Up
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
$275M Supply Agreement With Israel for LUNARCOV19 Vaccine; More Deals Likely; Raise PT to $78
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Vaccine Phase 1/2 Trial to Begin Imminently; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Major Milestone Achieved: Arcturus Is Now a Clinical Stage mRNA Company
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
With Little COVID Impact, Full Speed Ahead for ARCT-810 Ph1 in NZ
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Recap: LUNAR-COV19 Emerges as STARR of the Show; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
1Q20 - More Evidence for Single Shot Against COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Catalent Partnership Raises the Profile of LUNAR-COV19 as a Leading Vaccine Candidate
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Vol. 39: Does Remdesivir Signal Light at the End of the Tunnel?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y